Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Journal
Journal of hepatology
Journal Volume
78
Journal Issue
2
Pages
281
Date Issued
2023-02
Author(s)
Tsai, Pei-Chien
Kuo, Hsing-Tao
Hung, Chao-Hung
Tseng, Kuo-Chih
Lai, Hsueh-Chou
Peng, Cheng-Yuan
Wang, Jing-Houng
Chen, Jyh-Jou
Lee, Pei-Lun
Chien, Rong-Nan
Yang, Chi-Chieh
Lo, Gin-Ho
Yan, Sheng-Lei
Bair, Ming-Jong
Lin, Chun-Yen
Su, Wei-Wen
Chu, Cheng-Hsin
Chen, Chih-Jen
Tung, Shui-Yi
Tai, Chi-Ming
Lin, Chih-Wen
Lo, Ching-Chu
Cheng, Pin-Nan
Chiu, Yen-Cheng
Wang, Chia-Chi
Cheng, Jin-Shiung
Tsai, Wei-Lun
Lin, Han-Chieh
Huang, Yi-Hsiang
Yeh, Ming-Lun
Huang, Chung-Feng
Hsieh, Meng-Hsuan
Huang, Jee-Fu
Dai, Chia-Yen
Chung, Wan-Long
Chen, Chi-Yi
Yu, Ming-Lung
Abstract
Diabetes mellitus (DM) is known to increase the risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate whether metformin reduces HCC risk among individuals with DM and CHC after successful antiviral therapy.
Subjects
CHC; DM; HCC; HCV; Hepacivirus; Hepatitis C; Liver; SVR; antivirals; decompensated cirrhosis
Type
journal article